EcoDrugPlus

Toll Like Receptor 8

Ensembl ID : ENSLACG00000016637
Gene Symbol: TLR8
3 Cross references
200 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSLACG00000005388
Gene Symbol: LOC102360273
3 Cross references
600 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSLACG00000006111
Gene Symbol: LOC102360536
3 Cross references
600 Possible Orthologues:

Trace Amine-Associated Receptor 1-Like

Ensembl ID : ENSLACG00000002218
Gene Symbol: LOC102359819
4 Cross references
600 Possible Orthologues:

Transforming Growth Factor Beta Receptor 1

Ensembl ID : ENSLACG00000007257
Gene Symbol: TGFBR1
4 Cross references
230 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSLACG00000013023
Gene Symbol: TRPA1
3 Cross references
226 Possible Orthologues:

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSLACG00000014130
Gene Symbol: TRPM8
3 Cross references
158 Possible Orthologues:

Transthyretin

Ensembl ID : ENSLACG00000022231
Gene Symbol: TTR
4 Cross references
178 Possible Orthologues:

Tryptophan Hydroxylase 1

Ensembl ID : ENSLACG00000012424
Gene Symbol: TPH1
4 Cross references
256 Possible Orthologues:

Tubulin Alpha 1c

Ensembl ID : ENSLACG00000018970
Gene Symbol: TUBA1C
4 Cross references
78 Possible Orthologues:

Tubulin Alpha-1 Chain-Like

Ensembl ID : ENSLACG00000000977
Gene Symbol: LOC102345654
3 Cross references
5 Possible Orthologues:

Tubulin Beta 1 Class Vi

Ensembl ID : ENSLACG00000014731
Gene Symbol: TUBB1
4 Cross references
187 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).